P3 Health Partners sees FY25 revenue $1.35B-$1.5B, consensus $1.43B
FY25 Adjusted EBITDA Forecast: Sese's adjusted EBITDA for FY25 is projected to range between $69 million and $39 million.
Data Training Cutoff: The information provided is based on data available up to October 2023.
Trade with 70% Backtested Accuracy
Analyst Views on PIII
About PIII
About the author
P3 Health Partners Forms Joint Venture with Commonwealth to Expand Value-Based Care
- Joint Venture Formation: P3 Health Partners and Commonwealth Primary Care ACO have established a Joint Venture Management Services Organization aimed at expanding value-based care support across Arizona, California, Nevada, Oregon, and North Carolina, enhancing service capabilities for primary care physicians.
- Market Expansion: This partnership expands P3's footprint into Maricopa County, Arizona, further solidifying its position in a key growth market, which is expected to drive business growth in the region.
- Operational Efficiency Improvement: The joint venture combines P3's strengths in Medicare Advantage and ACO with Commonwealth's ACO REACH program to create a unified operational platform, thereby enhancing performance and efficiency in healthcare delivery.
- Physician Support Enhancement: The joint venture will strengthen support for independent primary care physicians by sharing operations and best practices, ensuring they can thrive and deliver exceptional care in a value-based environment.
Projected Target Price for ONEQ Analyst: $104
ETF Performance Analysis: The Fidelity Nasdaq Composite Index ETF (ONEQ) has an implied analyst target price of $103.84, indicating a potential upside of 10.75% from its current trading price of $93.76.
Notable Holdings: Key underlying holdings with significant upside potential include KODIAK ROBOTICS INC (KDK), Red Cat Holdings Inc (RCAT), and P3 Health Partners Inc (PIII), with expected price increases of 96.58%, 62.44%, and 58.15% respectively.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent company and industry developments.
Catalyst Solutions Successfully Launches P3 Implementation in Four States
Successful Implementation: Catalyst Solutions has successfully launched the Professional Health Partners Services (P3) Implementation, which began in May 2025, enhancing services for Medicare members across multiple states.
Operational Support: The implementation supports eleven health plans and nearly 68,000 members in Arizona, Oregon, Nevada, and California, with additional support for a new Medicare plan on the way.
Partnership Recognition: Both Catalyst Solutions and P3 Health Partners express pride in their collaboration, highlighting the effective execution of the project within a tight 60-day timeframe.
Commitment to Improvement: Catalyst Solutions aims to drive value through agile implementations and operational expertise, focusing on improving health outcomes and cost efficiency for health plans.
P3 Health Partners Inc. (PIII) Q2 2025 Earnings Call Transcript
Earnings Conference Call Overview: P3 Health Partners Inc. held its Q2 2025 earnings conference call on August 14, 2025, featuring key participants including the CEO, CFO, and various analysts from investment firms.
Forward-Looking Statements Disclaimer: The call included forward-looking statements regarding the company's financial outlook, emphasizing that these predictions are subject to risks and uncertainties that could lead to actual results differing from expectations.
P3 Health (PIII) Q2 2025 Earnings Call Transcript
- Author's Perspective: The opinions shared in the article are solely those of the author and do not represent Nasdaq, Inc.
- Data Limitations: The information is based on data available up to October 2023.
P3 Health Partners Posts Q2 Revenue Drop
Earnings Report Overview: P3 Health Partners reported Q2 FY2025 results with both GAAP revenue and non-GAAP earnings per share missing analyst estimates, alongside a significant adjusted EBITDA loss. The company experienced a 9% decline in average at-risk membership year-over-year, primarily due to rationalization efforts in its network.
Operational Challenges and Future Outlook: Despite improvements in medical cost management and clinical initiatives, P3's consolidated losses are heavily influenced by one underperforming market. Management anticipates continued challenges, projecting revenues between $1.35 billion and $1.5 billion for the year, while identifying potential EBITDA improvement opportunities for 2026.
P3 Health Partners Forms Joint Venture with Commonwealth to Expand Value-Based Care
- Joint Venture Formation: P3 Health Partners and Commonwealth Primary Care ACO have established a Joint Venture Management Services Organization aimed at expanding value-based care support across Arizona, California, Nevada, Oregon, and North Carolina, enhancing service capabilities for primary care physicians.
- Market Expansion: This partnership expands P3's footprint into Maricopa County, Arizona, further solidifying its position in a key growth market, which is expected to drive business growth in the region.
- Operational Efficiency Improvement: The joint venture combines P3's strengths in Medicare Advantage and ACO with Commonwealth's ACO REACH program to create a unified operational platform, thereby enhancing performance and efficiency in healthcare delivery.
- Physician Support Enhancement: The joint venture will strengthen support for independent primary care physicians by sharing operations and best practices, ensuring they can thrive and deliver exceptional care in a value-based environment.
Projected Target Price for ONEQ Analyst: $104
ETF Performance Analysis: The Fidelity Nasdaq Composite Index ETF (ONEQ) has an implied analyst target price of $103.84, indicating a potential upside of 10.75% from its current trading price of $93.76.
Notable Holdings: Key underlying holdings with significant upside potential include KODIAK ROBOTICS INC (KDK), Red Cat Holdings Inc (RCAT), and P3 Health Partners Inc (PIII), with expected price increases of 96.58%, 62.44%, and 58.15% respectively.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they are based on outdated information.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analysts' targets in light of recent company and industry developments.
Catalyst Solutions Successfully Launches P3 Implementation in Four States
Successful Implementation: Catalyst Solutions has successfully launched the Professional Health Partners Services (P3) Implementation, which began in May 2025, enhancing services for Medicare members across multiple states.
Operational Support: The implementation supports eleven health plans and nearly 68,000 members in Arizona, Oregon, Nevada, and California, with additional support for a new Medicare plan on the way.
Partnership Recognition: Both Catalyst Solutions and P3 Health Partners express pride in their collaboration, highlighting the effective execution of the project within a tight 60-day timeframe.
Commitment to Improvement: Catalyst Solutions aims to drive value through agile implementations and operational expertise, focusing on improving health outcomes and cost efficiency for health plans.
P3 Health Partners Inc. (PIII) Q2 2025 Earnings Call Transcript
Earnings Conference Call Overview: P3 Health Partners Inc. held its Q2 2025 earnings conference call on August 14, 2025, featuring key participants including the CEO, CFO, and various analysts from investment firms.
Forward-Looking Statements Disclaimer: The call included forward-looking statements regarding the company's financial outlook, emphasizing that these predictions are subject to risks and uncertainties that could lead to actual results differing from expectations.
P3 Health (PIII) Q2 2025 Earnings Call Transcript
- Author's Perspective: The opinions shared in the article are solely those of the author and do not represent Nasdaq, Inc.
- Data Limitations: The information is based on data available up to October 2023.
P3 Health Partners Posts Q2 Revenue Drop
Earnings Report Overview: P3 Health Partners reported Q2 FY2025 results with both GAAP revenue and non-GAAP earnings per share missing analyst estimates, alongside a significant adjusted EBITDA loss. The company experienced a 9% decline in average at-risk membership year-over-year, primarily due to rationalization efforts in its network.
Operational Challenges and Future Outlook: Despite improvements in medical cost management and clinical initiatives, P3's consolidated losses are heavily influenced by one underperforming market. Management anticipates continued challenges, projecting revenues between $1.35 billion and $1.5 billion for the year, while identifying potential EBITDA improvement opportunities for 2026.
